ArticleClinical autonomic research : official journal of the Clinical Autonomic Research Society2008
Pilot study of pyridostigmine in constipated patients with autonomic neuropathy.
Article in Clinical autonomic research : official journal of the Clinical Autonomic Research Society, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Vincristine-induced ptosis in pediatric patients: a systematic review and practice recommendations.European journal of pediatrics · 2025Pooled it
- Guideline
- Effects of ondansetron on symptoms during a gastric emptying study and enteral lipid challenge and on daily symptoms in diabetic gastroenteropathy.Neurogastroenterology and motility · 2024Trial
- A pharmacological challenge predicts reversible rectal sensorimotor dysfunctions in women with fecal incontinence.Neurogastroenterology and motility · 2018Trial
- Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders.Neurogastroenterology and motility · 2015Trial
- Trial
- Potential role of pyridostigmine in the management of pediatric chronic intestinal pseudo-obstruction in a girl with ACTL6B mutation: a case report and a review of literature.Frontiers in pediatrics · 2026Article
- Suspected Pyridostigmine-Related Hepatotoxicity.ACG case reports journal · 2026Article
- Parkinson's disease and metabolic disorders, understanding their shared co-morbidity through the autonomic nervous system.Advances in genetics · 2025Review
- Update on the Treatment of Autonomic Disorders.Current treatment options in neurology · 2025Article
- Anticipating Tomorrow: Tailoring Parkinson's Symptomatic Therapy Using Predictors of Outcome.Movement disorders clinical practice · 2024Article
- Managing gastrointestinal manifestations in systemic sclerosis, a mechanistic approach.Expert review of clinical immunology · 2024Review
- Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management.Nature reviews. Rheumatology · 2023Review
- Exploring Pharmacological Treatments for Chronic Idiopathic Constipation in Adults: A Look Back to the Future.Journal of clinical medicine · 2023Review
- Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders.Alimentary pharmacology & therapeutics · 2021Review
- Recent Advances in the Management of Severe Gastrointestinal Dysmotility.Clinical and experimental gastroenterology · 2021Review
- Relationship between symptoms during a gastric emptying study and intestinal chemosensitivity with daily symptoms.Neurogastroenterology and motility · 2019Article
- Pyridostigmine Suicidal Attempt in a Myasthenia Gravis Patient.The American journal of case reports · 2019Article
- Colonic and Anorectal Manifestations of Systemic Sclerosis.Current gastroenterology reports · 2019Review
- Personalized medicine in functional gastrointestinal disorders: Understanding pathogenesis to increase diagnostic and treatment efficacy.World journal of gastroenterology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe effects of cholinesterase inhibitors, which increase colonic motility in health, on chronic constipation are unknown. Our aims were to evaluate the efficacy of cholinesterase inhibitors for dysautonomia and chronic constipation and to assess whether acute effects could predict the long term response.
methodsIn this single-blind study, 10 patients with autonomic neuropathy and constipation were treated with placebo (2 weeks), followed by an escalating dose of pyridostigmine to the maximum tolerated dose (i.e., 180-540 mg daily) for 6 weeks. Symptoms and gastrointestinal transit were assessed at 2 and 8 weeks. The acute effects of neostigmine on colonic transit and motility were also assessed.
resultsAt baseline, 4, 6, and 3 patients had delayed gastric, small intestinal, and colonic transit respectively. Pyridostigmine was well tolerated in most patients, improved symptoms in 4 patients, and accelerated the geometric center for colonic transit at 24 h by > or =0.7 unit in 3 patients. The effects of i.v. neostigmine on colonic transit and compliance predicted (P < 0.05) the effects of pyridostigmine on colonic transit.
conclusionsPyridostigmine improves colonic transit and symptoms in some patients with autonomic neuropathy and constipation. The motor response to neostigmine predicted the response to oral pyridostigmine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.